Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stock
Lyka Labs Limited is a pharmaceutical company initially focused on formulations and bulk drugs, later expanding into a diverse array of healthcare products.
The company has a broad portfolio including antibiotics, cardiac drugs, anti-inflammatory products, and unique offerings like dextromethorphan hydrobromide lozenges in India.
Post-2016, Lyka merged its subsidiaries, bolstering its focus on domestic markets and ethical products.
Significant equity acquisition by IPCA and partners in 2021-22 established them as joint promoters, signaling strategic alignment.
In 2023, Lyka acquired the animal healthcare business of Agilis Healthcare, enhancing its veterinary portfolio.
Pharmaceuticals & Biotechnology
Pharmaceuticals
247 Cr
Moderate Risk
-24.7
34.3
—
2.7
125.00
44.49
Sales CAGR
Profit CAGR
ROE
ROCE
Bearish
6
Neutral
4
Bullish
4
Bearish
10
Neutral
4
Bullish
32
Bearish
4
Neutral
0
Bullish
28
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Lyka Labs Ltd (LYKALABS) is currently trading at 69.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Lyka Labs Limited is a pharmaceutical company initially focused on formulations and bulk drugs, later expanding into a diverse array of healthcare products. The company has a broad portfolio including antibiotics, cardiac drugs, anti-inflammatory products, and unique offerings like dextromethorphan hydrobromide lozenges in India. Post-2016, Lyka merged its subsidiaries, bolstering its focus on domestic markets and ethical products. Significant equity acquisition by IPCA and partners in 2021-22 established them as joint promoters, signaling strategic alignment. In 2023, Lyka acquired the animal healthcare business of Agilis Healthcare, enhancing its veterinary portfolio.
Over the past 52 weeks, Lyka Labs Ltd has traded between a low of ₹44.49 and a high of ₹125.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Lyka Labs Ltd has a market capitalization of approximately 247.44. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Lyka Labs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -24.65 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 247.44 Cr, Lyka Labs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Lyka Labs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Lyka Labs Ltd is -24.65. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
10.59 | 257 Cr | 13.83 | 1.16 | 0.00 | 8.29 | 9.09 | 6.02 | ||
243.70 | 256 Cr | 56.67 | 4.48 | 0.00 | 7.90 | 8.87 | 3.09 | ||
32.40 | 248 Cr | 13.95 | 1.57 | 0.00 | 11.24 | 10.51 | 6.33 | ||
258.90 | 248 Cr | 44.52 | 3.28 | 0.00 | 7.35 | 11.62 | 2.32 | ||
69.50 | 247 Cr | -24.65 | 2.68 | 0.00 | -10.86 | -6.04 | -5.98 | ||
408.40 | 232 Cr | 21.46 | 3.07 | 1.24 | 14.04 | 19.30 | 10.92 | ||
11.82 | 229 Cr | -0.78 | 0.39 | 0.00 | -9.85 | -8.75 | -47.12 | ||
| Median: 7 Co. | — | 69.50 | 248 Cr | 13.95 | 2.68 | 0.00 | 7.90 | 9.09 | 3.09 |
Share Allotment (Amalgamation)
Lyka Labs approved allotment of 462,711 equity shares to Lyka Exports shareholders under the NCLT‑sanctioned amalgamation (23:100 ratio; record date June 4, 2026), raising paid-up capital to Rs.36,15,27,110; shares to be listed and rank pari-passu.
Share Allotment
Board approved allotment of 462,711 equity shares to Lyka Exports shareholders at a ratio of 23:100 under the sanctioned scheme of amalgamation, raising paid-up capital to Rs.36,15,27,110 (3,61,52,711 shares); shares to be listed on BSE/NSE.
